Project Grant R21EY039036
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $491K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Similar Awards
- The National Eye Institute awarded The Trustees of Columbia University in the City of New York $532,079 on September 1, 2026, under the Vision Research program (CFDA 93.867) to characterize the role of apelin signaling in Schlemm's canal development and its relationship to early-onset glaucoma. The research employs mouse models to express and trace the apelin receptor during Schlemm's canal development, uses conditional and inducible mouse models to study loss of apelin receptor function...
- The National Eye Institute awarded The Schepens Eye Research Institute $858,394 on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop multimodal foundation models for eye disease screening and prognosis. The research develops a vision-language foundation model trained on pairs of retinal images and clinical notes to enable downstream supervised models for detection and progression prediction of age-related macular degeneration, diabetic retinopathy, and glaucoma. The...
- The National Eye Institute awarded The Schepens Eye Research Institute $545,948 on April 1, 2026, under the Vision Research program (CFDA 93.867) to support Project Grant R01EY037230, "Understanding the Role of Reactive Astrocytes in Glaucoma." The award funds research into how astrocytes—the primary cellular component of the optic nerve head—become reactive in glaucoma and alter their support of retinal ganglion cells. The project investigates metabolic changes in astrocytes exposed...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $481,250 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective June 1, 2025 through May 31, 2027. The award funds research investigating the molecular mechanisms by which mutations in the ADAMTS10 gene contribute to primary open-angle glaucoma (POAG), a leading cause of irreversible blindness. The research employs genetically modified mouse models carrying...
- The National Eye Institute (NEI) awarded $764,881 to the University of Colorado-Denver under the Vision Research program (CFDA 93.867) on September 15, 2025, to support a two-year research project investigating the role of advanced glycation end products (AGEs) in primary open-angle glaucoma (POAG). The project will generate fundamental research findings and preclinical data on how AGEs accumulate in trabecular meshwork (TM) tissues and contribute to elevated intraocular pressure and optic nerve...
- The National Eye Institute awarded The New England College of Optometry $371,997 on June 1, 2026, under the Vision Research program (CFDA 93.867) to test a novel emmetropization mechanism model based on spectral and spatial opponent information in young children with myopia. The project will investigate how the retina controls eye growth and refraction through a blue-versus-yellow spectral-opponent mechanism. The research tests whether imbalances in retinal spectral and spatial...
- The National Eye Institute awarded Baylor College of Medicine $100,228 on March 22, 2027, under the Vision Research program (CFDA 93.867) to validate endothelial mediators in glaucoma neurovascular dysfunction using ligandomics technology. The recipient will independently validate the binding selectivity of glaucoma-associated endothelial ligands to ocular hypertensive versus healthy retinal vessels and verify their functional roles in retinal ganglion cell loss and neurovascular dysfunction...
- The National Eye Institute, part of the National Institutes of Health within the Department of Health and Human Services, awarded Creighton University $350,000 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support discovery and development of novel trifunctional hybrid compounds for glaucoma therapy. The funded research focuses on designing and evaluating trifunctional hybrid compounds that integrate three disease-modifying entities—an FP...
- The National Eye Institute awarded The Washington University $427,625 under the Vision Research program (CFDA 93.867) on April 1, 2026, to develop novel statistical methodologies for detecting visual field progression in primary open-angle glaucoma using data from the Ocular Hypertension Treatment Study. The project delivers three core products: a change-point model for mean deviation progression that integrates longitudinal measures with time-to-detectable-change to identify early disease...
- Summary The National Eye Institute (NEI), under its Vision Research program (CFDA 93.867), awarded $417,162 to the University of Houston System for a two-year project (July 1, 2025 – June 30, 2027) investigating the birefringence properties of the lamina cribrosa and posterior eye structures as they relate to glaucoma detection and diagnosis. The project addresses a critical clinical need by developing advanced optical imaging methodologies to detect early structural and stress-related changes...